<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01514838</url>
  </required_header>
  <id_info>
    <org_study_id>1941-CL-2003</org_study_id>
    <nct_id>NCT01514838</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase III, Double-Blind, Randomized, Active Controlled, Monotherapy Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of ASP1941 based on the changes in HbA1C
      as well as its safety in Asian subjects with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, active-controlled, double-blind, double-dummy, parallel-group
      comparative study. After a screening period followed by a placebo run-in period under the
      single-blind condition, subjects will be randomized to either the ASP1941 or the acarbose
      group. Subjects will take the study drug under the double-blind condition in the treatment
      period. After completion of the study drug administration, a follow-up period will be
      provided.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Discontinued due to company's strategic reason
  </why_stopped>
  <start_date type="Actual">April 23, 2012</start_date>
  <completion_date type="Actual">October 19, 2012</completion_date>
  <primary_completion_date type="Actual">October 19, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c from baseline to end of treatment</measure>
    <time_frame>Baseline and up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose level</measure>
    <time_frame>Baseline and up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum insulin level</measure>
    <time_frame>Baseline and up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Baseline and up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body waist circumference</measure>
    <time_frame>Baseline and up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs safety labo-tests and 12-lead ECG</measure>
    <time_frame>For 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1941 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily over a 24-week treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acarbose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily over a 24-week treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1941</intervention_name>
    <description>oral</description>
    <arm_group_label>1941 group</arm_group_label>
    <other_name>ipragliflozin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acarbose</intervention_name>
    <description>oral</description>
    <arm_group_label>acarbose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral, used only during placebo run-in period</description>
    <arm_group_label>1941 group</arm_group_label>
    <arm_group_label>acarbose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed as type 2 diabetes mellitus patient at least 12 weeks before the study

          -  stable diet and exercise program for at least 6 weeks before the study

          -  for the hypoglycemic agent non-naïve subject, subject has been receiving a single
             hypoglycemic agent or low-dose of a dual combination therapy

          -  BMI of 20.0 to 45.0 kg/m2

          -  for the hypoglycemic agent non-naïve subject, subject has a HbA1c value between 6.8
             and 10.0% at screening AND has a HbA1c value between 7.0 and 10.0%, inclusive, at
             run-in period

          -  for the hypoglycemic agent naïve subject, subject has a HbA1c value between 7.0 and
             10.0%, inclusive, at run-in period

        Exclusion Criteria:

          -  type 1 diabetes mellitus

          -  proliferative diabetic retinopathy

          -  receiving insulin within 12 weeks prior to the study

          -  history of clinically significant renal disease(s)

          -  significant dysuria caused by a neurogenic bladder or a benign prostate hypertrophy
             etc.

          -  urinary tract infection or genital infection

          -  continuous use of systemic corticosteroids, immunosuppressants, or loop diuretics

          -  history of cerebrovascular attack, unstable angina, myocardial infarction,
             angioplasty, serious cardiac diseases within 12 weeks prior to the study

          -  severe infection, serious trauma, or perioperative subject

          -  known or suspected hypersensitivity to ASP1941, acarbose or other alpha-GI

          -  history of treatment with ASP1941

          -  participated in another clinical study, postmarketing study or medical device study
             within 12 weeks before the study

          -  serum creatinine value exceeding the upper limit of normal range

          -  urinary microalbumin/urinary creatinine ratio &gt;300 mg/g
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changha</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=108</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2012</study_first_posted>
  <last_update_submitted>December 13, 2018</last_update_submitted>
  <last_update_submitted_qc>December 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urine glucose</keyword>
  <keyword>ipragliflozin</keyword>
  <keyword>plasma glucose</keyword>
  <keyword>ASP1941</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acarbose</mesh_term>
    <mesh_term>Ipragliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

